about
Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regenerationRapid identification of imported influenza viruses at Xiamen International Airport via an active surveillance program.Detection of HBV Covalently Closed Circular DNAThe development of a recombinant hepatitis E vaccine HEV 239.A lysine-rich motif in the phosphatidylserine receptor PSR-1 mediates recognition and removal of apoptotic cells.A valuable antigen detection method for diagnosis of acute hepatitis E.Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Construction and characterization of an infectious cDNA clone of Echovirus 25.Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71.A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus.Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study.Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human seraDetection and analysis of tupaia hepatocytes via mAbs against tupaia serum albumin.The ORF3 Protein of Genotype 1 Hepatitis E Virus Suppresses TLR3-induced NF-κB Signaling via TRADD and RIP1.A fast and low-cost genotyping method for hepatitis B virus based on pattern recognition in point-of-care settings.Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model.Virus-like particle-based human vaccines: quality assessment based on structural and functional properties.Lessons from hepatitis E vaccine design.Insights into the function of tegument proteins from the varicella zoster virus.Functional assessment and structural basis of antibody binding to human papillomavirus capsid.Functional analysis of human cytomegalovirus UL/b' region using SCID-hu mouse model.Sleeping Beauty transposon-based system for rapid generation of HBV-replicating stable cell lines.The prevalence of latent tuberculosis infection in rural Jiangsu, China.Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody.Development of an enzyme-linked immunospot assay for determination of rotavirus infectivity.Construction and characterization of an infectious clone of coxsackievirus A6 that showed high virulence in neonatal mice.Calcium phosphate nanoparticles as a new generation vaccine adjuvant.Characterization and analysis of real-time capillary convective PCR toward commercialization.Severe hand, foot and mouth disease associated with Coxsackievirus A10 infections in Xiamen, China in 2015.Identification of Strategic Residues at the Interface of Antigen-Antibody Interactions by In Silico Mutagenesis.Stop codon mutagenesis for homogenous expression of human papillomavirus L1 protein in Escherichia coli.Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.Quantitative and epitope-specific antigenicity analysis of the human papillomavirus 6 capsid protein in aqueous solution or when adsorbed on particulate adjuvants.Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.Production of Influenza Virus HA1 Harboring Native-Like Epitopes by Pichia pastoris.Evaluation of a novel chemiluminescent microplate enzyme immunoassay for hepatitis B surface antigen detection.Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine.Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate.
P50
Q27727708-1507F116-D588-4F87-AF7E-63508C2A5B59Q30402782-2D9FB909-5F41-48F9-83F7-2D0305938BAAQ32183310-A026E14C-DDF6-4D51-9444-546D5EF71743Q34464464-3537FB58-314A-4876-8FB4-4147455599CCQ35013249-40215697-B08A-41A9-AD81-8F5C958159F2Q35331616-9682DFA6-20E9-42C3-8A19-CDAA6B315642Q35532771-12041413-9E0E-4BE4-B19D-3E1AC9263901Q35640256-8F17188B-2EBF-4283-9138-BF4E614F330EQ35887653-922DB29C-2AD2-4EED-9201-6B709022CFAFQ35917729-A7F5E2A2-8490-471F-BB0E-B71360BF860DQ36073689-F58FE743-FA03-46D8-AF7B-87F605338549Q36151658-E53229D9-3A9C-422D-A832-897E9F3CFB0DQ36700993-3939C6DA-0FAB-4689-A4FD-F551BD6C6FE0Q36918300-4F4DE5C5-1557-4BFE-8F6B-8A416024296CQ36980637-2CEE2B69-CA17-44C6-9A22-CE10BD439A3AQ37011078-D7549256-3007-4237-BE1E-165186FAE6CBQ37473348-C50B85E8-1B3E-43F7-9C87-0CF3D17FC403Q38152530-914FC5B7-E486-45E7-AE9D-13A07AD58471Q38443172-4AA92F36-30C4-4283-B675-2E55F27AE73FQ38553727-BB4F23E1-E247-44E0-9400-9B5FF2E566ACQ38671633-E7BB8D94-C59F-453D-8652-453FDDBDEF8FQ38767171-E5D08F5E-703F-4F2C-8FF9-B46768C91702Q38777289-5D1399F6-38B1-4E7E-8C86-AD7ED70EE939Q38839667-FAE5388D-3C53-4D76-B154-985CF2ECDCE0Q38844810-13D75C67-DAD8-406D-AB4D-3D49D43C4A17Q38961657-51E1C474-862A-4795-8BE7-B998A0DCBA1EQ38974389-F3472F8D-72D3-4227-88E7-175FE1797370Q39437472-47178D95-9678-465F-AD02-6AF292DB389EQ40086433-9485896F-76FF-49BF-ACE1-B636EBB59B79Q40186615-7F5C2A31-211A-45D4-B5C5-4D15A2936BC9Q40191458-8CD5D8D0-EA25-4AFC-B036-96DD08134B92Q40304863-FC9C1F63-124C-4C4C-983F-FF53E16E66B4Q40477519-7A44A576-0DD5-4A2C-8C5B-A15209BE2AF2Q40610561-37D4C177-701F-4AF6-B3AF-F66A42193FBEQ40651549-D6E57F1E-2C04-4D4D-90F2-3D16DC7D4648Q40730375-1DFD5580-161A-4AA3-B927-41865E7BE25EQ40891223-A7777260-ABCE-429F-8D70-F5B68379BD1DQ41145359-02583C62-6F80-4E7A-8B80-FCC0C11C6E1CQ41264182-876550AD-165F-4117-8617-AB63BEB01FEAQ41326217-F1B33DAE-7013-48C0-8E4C-299671CE1FBA
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-0179-5266
@en
name
Ningshao Xia
@ast
Ningshao Xia
@en
Ningshao Xia
@es
Ningshao Xia
@nl
type
label
Ningshao Xia
@ast
Ningshao Xia
@en
Ningshao Xia
@es
Ningshao Xia
@nl
prefLabel
Ningshao Xia
@ast
Ningshao Xia
@en
Ningshao Xia
@es
Ningshao Xia
@nl
P106
P31
P496
0000-0003-0179-5266